INTRODUCTION
Cytotoxic cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of lymphoproliferative disorders characterized by localization of atypical T cells in the skin that often express CD56 and cytotoxic granules. CTCLs exhibit a wide range of clinical and histopathologic features but tend to be aggressive. 1 Often diagnosis relies heavily on immunohistochemistry. We report a case of cytotoxic CTCL with a unique immunophenotype.
CASE REPORT
A 69-year-old white man had annular plaques on sun-exposed areas of his body. Two lesional biopsies found a lymphocytic infiltrate lacking atypia and monoclonality. Diffuse dermal mucin deposition was observed, consistent with tumid lupus. The patient was treated with topical fluocinonide cream and hydroxychloroquine, 400 mg daily, later increased to 600 mg, with significant improvement. Three months later skin lesions of a different morphology developed: nodules on his upper arms and thighs that enlarged and involuted spontaneously. Lesional biopsies of the right arm and right leg found an atypical population of CD3 1 , CD56
1 , and CD4/CD8 double negative (DN) lymphocytes of medium to large size, consistent with CTCL. Hydroxychloroquine was discontinued, and the patient's nodules resolved.
When the patient presented to us, he had a 1-cm ill-defined indurated nodule on his back, an arcuate lesion on his upper abdomen, and several erythematous patches in sun-exposed areas. A biopsy of the nodule found a predominantly CD3 1 infiltrate with a normal CD4:CD8 ratio, preserved CD7 expression, and negative CD30 and CD56 expression. There was a mild increase in dermal mucin, consistent with the original diagnosis of tumid lupus. A repeat biopsy 2 weeks later showed only perifollicular granulomatous inflammation. Bone marrow biopsy, peripheral blood flow cytometry, and positron emission tomography/computed tomography (PET/CT) scan were within normal limits. At follow-up 6 months later, the patient remained free of all lesions suggestive of lymphoma.
Two years later, the patient returned with new violaceous annular plaques on the left popliteal fossa, right forearm, and the left thigh (Fig 1, A) , and CD4/CD8 DN by immunohistochemistry (Fig 2, A-C ). TIA1 and granzyme B were positive, and Epstein-Barr viruseencoded small RNAs (EBER) by in situ hybridization were negative. T-cell receptor (TCR) gene rearrangement studies showed bF1 1 and TCRg À . PET/CT and peripheral blood flow cytometry were again unremarkable. The lesions responded to 8 Gy of local electron beam radiation (Fig 1, B) . Five months later, the patient had new lesions on his forearms and left thigh. The patient was treated again with local electron beam, with near-complete response to therapy.
DISCUSSION
CTCLs have a wide spectrum of clinical presentations, making lesional biopsy tantamount to diagnosis. Classification of CTCLs follows World Health Organization (WHO)eEuropean Organization for Research and Treatment of Cancer (EORTC) guidelines using clinical, histologic, immunophenotypic, and genetic features. 2 However, diagnoses are often made based on histopathology alone.
We report an unusual case of CTCL with an unusual CD3
1 cytotoxic immunophenotype that is not easily classified under the current WHO-EORTC guidelines. 2, 3 Several other cytotoxic CTCL entities were considered in the differential diagnosis, including subcutaneous panniculitic cutaneous T-cell lymphoma (SPTCL), primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL), extranodal natural killer (NK)/TCL, cutaneous anaplastic large cell lymphoma, and CD8 1 aggressive epidermotropic CTCL (Table I) . Although our patient's CTCL had a CD4/CD8 DN, CD56 1 phenotype, and cytotoxic molecule expression (TIA1, perforin, granzyme B), features suggestive of PCGD-TCL and extranodal NK/T-cell lymphoma, the expression of the bF1 TCR precludes classification as a PCGD-TCL. bF1 positivity is seen in SPCTLs, which can also express CD56 and cytotoxic molecules and typically exhibits an indolent course, but the patient's lack of subcutaneous involvement is inconsistent with such. 2, 4 The negative EBER challenged the diagnosis of extranodal NK/T-cell lymphoma. 2, 3 Primary cutaneous anaplastic large cell lymphoma is rarely CD56
1 , but its diagnosis requires more than 75% CD30 positivity, a feature this case consistently lacked. 2 It is important to note that the EBER staining method detects Epstein-Barr virus RNA by in situ hybridization. False-negative readings result from RNA degradation in the tissue and can be prevented with controls such as the polyT probe. 5 We routinely use positive and negative controls for our in situ hybridization for EBER.
Only rarely have CD3 1 , CD4/CD8 DN CTCLs been reported and most possess the g/d TCR unlike our patient's variant, which is bF1 1 /g À l, indicating an a/b phenotype. 6, 7 In a study of 48 cases of cytotoxic CTCLs, 5 cases of CD4/CD8 DN peripheral T-cell lymphoma (PTCL) unspecified were reported. Two of these cases were bF1 1 . It is unknown whether CD56 was positive in these cases. It was noted that a subset of unspecified PTCLs are indolent. 8 There is an uncommon variant of epidermotropic mycosis fungoides that is CD4/CD8 DN and bF1 1 /g À and portends an indolent course. 6 Otherwise, most CD4/CD8 DN lymphomas exhibit an aggressive course that is often refractory to treatment. 7 CD56 is a nonspecific marker of NK cells and is not only seen in NK lymphomas but also in PCGD-TCLs, another aggressive disease. 2, 3 The concomitant expression of CD56 and a/b TCR with cytotoxic granule proteins has not been previously described.
The patient's initial diagnosis with tumid lupus and lymphomatous lesions that spontaneously resolved is also unusual. Given that early-stage CTCL can mimic benign conditions, the patient's presentations likely represent one clinical entity. Under WHO-EORTC guidelines, this patient's disease is best classified as a peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). 2, 3 Because PTCL-NOS can be systemic, complete lymphoma staging was done to screen for blood, lymph node, and bone marrow involvement using peripheral blood flow cytometry, PET-CT, and bone marrow biopsy. There is no standard treatment for PTCL-NOS. The patient was treated with skindirected electron beam therapy because he has stage I disease limited to the skin.
